Axogen closes BioCircuit acquisition, adding FDA-cleared NerveTape; sees ~$34M 2027 revenue contribution

Axogen, Inc.

Axogen completed its acquisition of privately held BioCircuit Technologies, Inc. on October 1, 2026, adding NerveTape, described as the first FDA-cleared device for sutureless peripheral nerve repair.
BioCircuit expected to contribute approximately $6 million to Q4 2026 revenue and approximately $34 million to 2027 revenue.
That contribution was not included in Axogen's most recently issued full-year 2026 guidance of at least 24% revenue growth.
Company continues to expect full-year 2026 gross margin of at least 73% and to be free cash flow positive.
CEO Michael Dale said NerveTape is 'simpler, faster, and more effective than microsuturing' and fits Axogen's direct sales and hospital contracting; purchase price not disclosed.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.